1,800
Participants
Start Date
January 6, 2025
Primary Completion Date
October 31, 2027
Study Completion Date
March 31, 2029
Intravenous Dexmedetomidine
Intravenous dexmedetomidine (1 μg/kg over 40 minutes, a maximal dose of 80 μg)
Sublingual Dexmedetomidine
Sublingual dexmedetomidine (120 μg)
Intravenous Placebo
Intravenous placebo of 0.9% saline administered over 40 minutes
Sublingual Placebo
Inert sublingual film
NOT_YET_RECRUITING
Columbia University Medical Center, New York
NOT_YET_RECRUITING
Montefiore Medical Center, The Bronx
NOT_YET_RECRUITING
University of Maryland School of Medicine, Baltimore
NOT_YET_RECRUITING
Duke University Hospital, Durham
NOT_YET_RECRUITING
Vanderbilt University Medical Center, Nashville
NOT_YET_RECRUITING
Northwestern University Feinberg School of Medicine, Chicago
NOT_YET_RECRUITING
Washington University School of Medicine, St Louis
NOT_YET_RECRUITING
University of Nebraska Medical Center, Omaha
NOT_YET_RECRUITING
University of Iowa Carver College of Medicine, Iowa City
RECRUITING
Massachusetts General Hospital, Boston
NOT_YET_RECRUITING
Beth Israel Deaconess Medical Center, Boston
NOT_YET_RECRUITING
Brigham and Women's Hospital, Boston
Massachusetts General Hospital
OTHER